General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Recarbrio (imipenem, cilastatin and relebactam)
Status:
Under consideration for negotiation
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of patients with the following infections caused by the designated susceptible Gram-negative microorganisms
Last updated October 7, 2026
Status:
Active negotiation
Manufacturer:
Medison Pharma Canada Inc.
Indication:
For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
Last updated October 7, 2026
Status:
Under consideration for negotiation
Manufacturer:
Horizon Therapeutics Canada
Indication:
As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive
Last updated October 1, 2026
Status:
Under consideration for negotiation
Manufacturer:
Horizon Therapeutics Canada
Indication:
Adults with immunoglobulin G4-related disease
Last updated October 1, 2026
Status:
Under consideration for negotiation
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
For the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older.
Last updated October 1, 2026
Lupron Depot (leuprolide acetate)
Status:
Active negotiation
Manufacturer:
AbbVie Corporation
Indication:
Advanced prostate cancer
Last updated September 25, 2026
Status:
Concluded with an LOI
Manufacturer:
BeOne Medicines (Canada) ULC
Indication:
In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Last updated September 25, 2026
Status:
Negotiation on hold
Manufacturer:
LEO Pharma Inc.
Indication:
Generalized pustular psoriasis (GPP)
Last updated September 25, 2026
Status:
Under consideration for negotiation
Manufacturer:
Janssen Inc.
Indication:
In combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent
Last updated September 23, 2026
Status:
Under consideration for negotiation
Manufacturer:
Ferring Canada Inc.
Indication:
For the treatment of mild to moderate ulcerative colitis
Last updated September 21, 2026